Sato K - Search Results

1

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.

Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T. Mizuuchi H, et al. Among authors: sato k. Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28. Cancer Sci. 2016. PMID: 26845230 Free PMC article.

2

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.

Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T. Suda K, et al. Among authors: sato k. Int J Cancer. 2014 Aug 15;135(4):1002-6. doi: 10.1002/ijc.28737. Epub 2014 Feb 4. Int J Cancer. 2014. PMID: 24458568

3

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.

Suda K, Mizuuchi H, Murakami I, Uramoto H, Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, Mitsudomi T. Suda K, et al. Among authors: sato k. Lung Cancer. 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Epub 2014 Jun 2. Lung Cancer. 2014. PMID: 24939008

4

Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.

Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T. Mizuuchi H, et al. Among authors: sato k. PLoS One. 2015 Apr 14;10(4):e0123901. doi: 10.1371/journal.pone.0123901. eCollection 2015. PLoS One. 2015. PMID: 25875914 Free PMC article.

5

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.

Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T. Kobayashi Y, et al. Among authors: sato k. Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23. Clin Cancer Res. 2015. PMID: 26206867

6

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, Mitsudomi T. Suda K, et al. Among authors: sato k. Sci Rep. 2015 Sep 24;5:14447. doi: 10.1038/srep14447. Sci Rep. 2015. PMID: 26400668 Free PMC article.

7

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.

Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T. Suda K, et al. Among authors: sato k. Lung Cancer. 2016 Jan;91:36-40. doi: 10.1016/j.lungcan.2015.11.016. Epub 2015 Nov 25. Lung Cancer. 2016. PMID: 26711932

8

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Terashima M, et al. Among authors: sato k. Clin Cancer Res. 2016 Jul 15;22(14):3663-71. doi: 10.1158/1078-0432.CCR-15-2093. Epub 2016 Jan 29. Clin Cancer Res. 2016. PMID: 26826182

9

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.

Sato K, Suda K, Shimizu S, Sakai K, Mizuuchi H, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T. Sato K, et al. PLoS One. 2016 Apr 21;11(4):e0154186. doi: 10.1371/journal.pone.0154186. eCollection 2016. PLoS One. 2016. PMID: 27100677 Free PMC article.

10

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.

Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T. Kobayashi Y, et al. Among authors: sato k. Mol Cancer Ther. 2017 Feb;16(2):357-364. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2. Mol Cancer Ther. 2017. PMID: 27913578

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,219 results

Search Page

Filters